This is an international site for VOTUBIA® (everolimus) and is intended for Health Care Professionals in the EU. The information on this site is based on the EU SmPC and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country via www.novartisoncology.com/contactus.
This medicinal product has been authorized under a so-called, conditional approvalTM scheme. This means that further evidence on this medicinal product is awaited. The European Medicines Agency will review new information on the product every year, and the EU SmPC will be updated as necessary.
Below is a list of the countries that host the VOTUBIA® website based on local label and in local language. They are intended for Healthcare Professionals (HCPs) only. Click on any of the links to be redirected to that country-level website.
This website is intended for Health Care Professionals in the EU. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information via www.novartisoncology.com/contactus.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC)
VOTUBIA® is indicated for the treatment of adult patients with renal angiomyolipoma with tuberous sclerosis complex (TSC) who are at risk of complications (based on factors such as tumour size, presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery.
The evidence is based on analysis of change in sum of angiomyolipoma volume.
VOTUBIA® is indicated for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery.
The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease-related symptoms, has not been demonstrated.
All fields are required.